Compounded semaglutide associated with at least 10 deaths ...
Nov 6, 2024 · CNN —. Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths ...
FDA Approves First Treatment to Reduce Risk of Serious Heart ...
Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults...
Ozempic reduces risk of serious illness and death in people ...
May 24, 2024 · Weekly injections of semaglutide medications like Ozempic significantly reduce the risk of serious kidney outcomes, major cardiovascular events and death among people who have type 2 diabetes and...
Ozempic linked to lower Alzheimer's risk in people with Type ...
Oct 24, 2024 · Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes, according to a study published Thursday in the...
Weight-loss drug Wegovy produces ‘largest benefit ever seen ...
Aug 25, 2023 · CNN — The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical...
Why Your Cardiologist May Prescribe Semaglutide (Wegovy)
Apr 2, 2024 · In 2023, a clinical trial called Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) showed that Wegovy can significantly reduce the risk of major heart events—this time in people with extra weight and a cardiovascular condition who don’t have diabetes.
FDA Approves New Drug Treatment for Chronic Weight …
Today, the U.S. Food and Drug Administration approved Wegovy (semaglutide) injection (2.4 mg once weekly) for chronic weight management in adults with obesity or overweight with at least one ...